POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.

Alexander M MenziesGeorgina V LongAmiee KohnHussein A TawbiJeffrey WeberKeith FlahertyGrant A McArthurPaolo A AsciertoYanina PflugerKarl LewisKaty K TsaiOmid HamidHans PrenenLuis FeinErjian WangCarolin GuenzelFan ZhangJoseph F KlehaAlessandra di PietroMichael A Davies

Published in: Neuro-oncology advances (2024)

Despite small patient numbers due to early trial termination, BMRR appeared similar between the SLI and ph2, and the ph2 safety profile appeared consistent with previous reports of standard-dose encorafenib in combination with binimetinib.

Keyphrases

high dose
wild type
low dose
clinical trial
study protocol

case report
phase iii
resting state
stem cell transplantation
phase ii

adverse drug
emergency department
randomized controlled trial
metastatic colorectal cancer
blood brain barrier

functional connectivity
open label
subarachnoid hemorrhage
double blind